

ALKERMES INC  
Form 8-K  
April 14, 2006

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): April 13, 2006

**ALKERMES, INC.**

(Exact Name of Registrant as Specified in its Charter)

**PENNSYLVANIA**

(State or Other Jurisdiction of  
Incorporation)

**1-14131**

(Commission  
File Number)

**23-2472830**

(I.R.S. Employer  
Identification No.)

**88 Sidney Street**

**Cambridge, Massachusetts**

(Address of principal executive offices)

**02139**

(Zip Code)

Registrant's telephone number, including area code: **(617) 494-0171**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Table of Contents**

**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

SIGNATURE

EXHIBIT INDEX

EX-99.1 Press release issued by Alkermes, Inc. on April 13, 2006

---

**Table of Contents**

**Item 8.01 Other Events**

On April 13, 2006, Alkermes, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) approved VIVITROL™ (naltrexone for extended-release injectable suspension) for the treatment of alcohol dependence.

**Item 9.01 Financial Statements and Exhibits**

**(d) Exhibits**

**Exhibit No.    Description**

99.1        Press release issued by Alkermes, Inc. on April 13, 2006

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALKERMES, INC.**

Date: April 14, 2006

By: /s/ James M. Frates  
James M. Frates  
Vice President, Chief Financial Officer  
and Treasurer

---

**Table of Contents**

**EXHIBIT INDEX**

- 99.1 Press release issued by Alkermes, Inc. on April 13, 2006 announcing that the U.S. Food and Drug Administration (FDA) approved VIVITROL™ (naltrexone for extended-release injectable suspension) for the treatment of alcohol dependence.